Osmetech: biomarker license gives it diagnostics edge

Osmetech says its exclusive license for a key biomarker gives the company a big edge in identifying potential adverse reactions to warfarin, a commonly used therapy used to fight thrombosis. "This marker in conjunction with variants from the two genes (CYP2C9 and VKORC1) recommended by the FDA will improve patient outcomes by reducing the overall complications of warfarin therapy, reduce costs in the health system and help provide a new standard of personalized care, " says CEO James White said. ''The fact that Osmetech has an exclusive license to this marker for warfarin testing, we believe will help position us as the leading diagnostic company in this area."

- check out this release
- read the article from Thompson Financial

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.